All Blogs

Jun 24, 2024

Quick facts The primary cause of DCM is understood to be genetic, leading to a focus on tailoring treatments based on the specific molecular origin. Genetic testing plays a crucial role in DCM, as numerous studies and case reports have demonstrated, serving as a vital tool for diagnosis, prognosis, familial scr...

Sep 24, 2024

DelveInsight forecasts that with the launch of 15+ emerging therapies alongside existing treatments, the ALS treatment market is anticipated to surpass USD 4 billion across the 7MM by 2034. Currently, there is no cure for ALS and no effective treatment to halt or reverse the progression of the disease. As per ou...

Jun 20, 2024

Boston Scientific Corporation Announced Definitive Agreement to Acquire Silk Road Medical, Inc., an Innovator in Stroke Prevention Technology On June 18, 2024, Boston Scientific Corporation, a global leader in medical technologies, announced the formal agreement to acquire Silk Medical, Inc., a medical device co...

Jun 19, 2024

Duchenne muscular dystrophy (DMD) is a severe genetic disorder primarily affecting young boys between the ages of two and three. As per Delveinsight’s estimates, there were approximately 16K DMD patients in 2023 in the United States, with ˜75% of the patients below the age of 15. This condition leads to progressive...

Jun 26, 2024

Asthma is a major noncommunicable disease that impacts both children and adults, and it is the most prevalent chronic condition among children. In 2019, ~262 million individuals were impacted by asthma, resulting in 455K deaths all over the world. More than 27 million individuals in the United States suffer from...

Jun 18, 2024

Takeda Reveals Phase III Results for Soticlestat (TAK-935) in Dravet and Lennox-Gastaut Syndromes Takeda revealed topline results from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind Phase III trial assessing soticlestat (TAK-935) plus standard care against plac...

Jun 17, 2024

Merck’s investment of $11.5 billion in acquiring Acceleron Pharma is expected to yield significant returns with the FDA’s approval of WINREVAIR (sotatercept), a pivotal component of the acquisition, for the treatment of pulmonary arterial hypertension. An estimated prevalence of pulmonary hypertension at the pop...

Jun 14, 2024

Bristol Myers Squibb’s PD-1 inhibitor, OPDIVO, has deep roots in Japan. In July 2014, MHLW approved OPDIVO to treat melanoma, marking it the first approved PD-1 inhibitor globally. About two years later, KEYTRUDA gained approval in Japan for the same indications (melanoma and NSCLC). This set the stage for fierce c...

Jun 13, 2024

Asensus Surgical Agreed to be Acquired by Karl Storz  On June 07, 2024, Asensus Surgical announced that it had entered a deal in which Karl Storz would acquire the company for 35¢ per share in cash. Karl Storz Endoscopy-America, a wholly-owned subsidiary of Germany-based Karl Storz, had agreed to acquire...

Jun 12, 2024

In contemporary healthcare, technological progress has profoundly reshaped how patients are treated. One such innovation that has revolutionized healthcare delivery is the development of infusion therapy devices. These devices have become indispensable tools in administering fluids, medications, and nutrients direc...